GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » Sloan Ratio %

Aethlon Medical (Aethlon Medical) Sloan Ratio % : -14.19% (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Aethlon Medical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Aethlon Medical's Sloan Ratio for the quarter that ended in Dec. 2023 was -14.19%.

As of Dec. 2023, Aethlon Medical has a Sloan Ratio of -14.19%, indicating there is a warning stage of accrual build up.


Aethlon Medical Sloan Ratio % Historical Data

The historical data trend for Aethlon Medical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical Sloan Ratio % Chart

Aethlon Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -9.86 -9.95 -1.54 -3.32

Aethlon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.47 -3.33 -6.44 -8.96 -14.19

Competitive Comparison of Aethlon Medical's Sloan Ratio %

For the Medical Devices subindustry, Aethlon Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aethlon Medical's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Aethlon Medical's Sloan Ratio % falls into.



Aethlon Medical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Aethlon Medical's Sloan Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2023 )-Cash Flow from Operations (A: Mar. 2023 )
-Cash Flow from Investing (A: Mar. 2023 ))/Total Assets (A: Mar. 2023 )
=(-12.03--10.505
--0.943)/17.509
=-3.32%

Aethlon Medical's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-12.249--10.511
--0.257)/10.437
=-14.19%

Aethlon Medical's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -2.467 (Mar. 2023 ) + -3.282 (Jun. 2023 ) + -3.034 (Sep. 2023 ) + -3.466 (Dec. 2023 ) = $-12.25 Mil.
Aethlon Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -2.947 (Mar. 2023 ) + -2.482 (Jun. 2023 ) + -2.704 (Sep. 2023 ) + -2.378 (Dec. 2023 ) = $-10.51 Mil.
Aethlon Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.011 (Mar. 2023 ) + -0.23 (Jun. 2023 ) + -0.007 (Sep. 2023 ) + -0.009 (Dec. 2023 ) = $-0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aethlon Medical  (NAS:AEMD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Aethlon Medical has a Sloan Ratio of -14.19%, indicating there is a warning stage of accrual build up.


Aethlon Medical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aethlon Medical (Aethlon Medical) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Executives
Nicolas Gikakis director 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa officer: Chief Medical Officer 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah director 9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr director C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani director 1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr officer: Interim CEO 201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R. 10 percent owner 10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley director, officer: President 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes officer: Chief Financial Officer 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr director 1141 DELAWARE AVENUE #3N, BUFFALO NY 14209